PCAC Backs 6 of 7 Peptides for 503A Compounding List: Full Vote Results

PCAC Backs 6 of 7 Peptides for 503A Compounding List

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) completed its two-day review of seven peptide compounds on July 23–24, 2026, recommending six for inclusion on the Section 503A Bulk Drug Substances List. Emideltide (DSIP) was the only compound rejected.

The votes were conducted at FDA’s White Oak campus and represent the most significant regulatory moment for the peptide compounding market since the 2023–2024 enforcement wave that removed several compounds from legal compounding access.

---

Full Vote Results

Compound	Day	Vote	Recommendation
BPC-157	July 23	8–6, 1 abstention	Include on 503A Bulks List
KPV (Lys-Pro-Val)	July 23	8–6, 1 abstention	Include on 503A Bulks List
TB-500 (Thymosin β-4)	July 23	8–6, 1 abstention	Include on 503A Bulks List
MOTS-c	July 23	7–5, 2 abstentions	Include on 503A Bulks List
Semax	July 24	Majority yes	Include on 503A Bulks List
Epitalon	July 24	Majority yes	Include on 503A Bulks List
Emideltide (DSIP)	July 24	Majority no	Do not include

---

What the Vote Actually Means

A PCAC recommendation is advisory — it is not a final regulatory action. The FDA is not legally required to follow the committee’s guidance. What happens next:

1. FDA publishes the committee’s recommendations and opens a public comment period (typically 60 days)
2. Formal rulemaking follows, during which compounding pharmacies, clinicians, researchers, and patient advocates can submit evidence
3. Final FDA determination — only after this process does the 503A Bulks List status change

Critically: the vote did not immediately authorize compounding pharmacies to produce any of these six compounds. Legal compounding under 503A still requires the full rulemaking process to complete.

---

Why the Votes Were Closer Than Expected

The FDA’s own briefing materials recommended against adding all seven compounds to the list. The committee reached a different conclusion — but the margins were not overwhelming. Most Day 1 votes landed at 8–6 with abstentions, reflecting genuine committee division on questions of:

• Substance characterization and purity standards
• Long-term human safety data (most evidence base is preclinical)
• The distinction between widespread anecdotal use and controlled clinical evidence

The committee ultimately weighted patient access, historical compounding use, and the existing research base more heavily than the FDA’s staff recommendations.

---

DSIP: The Outlier

Emideltide (DSIP) was the only compound rejected. Despite being an endogenous nonapeptide naturally produced by the hypothalamus and pituitary, the committee found the evidence base insufficient to recommend 503A inclusion. The endogenous origin argument — which gave DSIP advocates reason for optimism — did not carry the day.

---

What This Means for the Peptide Market

Short term: Nothing changes operationally. Compounds currently in Category 2 status remain there until FDA completes formal rulemaking. Compounders and patients should not treat the PCAC vote as a green light.

Medium term: A favorable committee recommendation meaningfully increases the probability of FDA adding these six compounds to the 503A list — but the timeline from vote to rulemaking completion has historically been 12–24 months.

Long term: This vote signals that the regulatory environment for research-supported peptides is moving toward access rather than restriction, a meaningful shift from the enforcement posture of 2023–2024.

---

The McDermott Law Analysis

Legal analysis from McDermott Will & Emery notes the committee backed the majority of peptides reviewed, despite FDA staff opposition — an outcome that reflects growing pressure from the compounding industry, patient advocates, and the clinical community to maintain access to compounds with meaningful (if preclinical-heavy) evidence bases.

The full McDermott analysis is available at: mcdermottlaw.com

---

Advisory committee recommendations are not final regulatory determinations. Ercle reports on regulatory developments for research and informational purposes only. See our full disclaimer.